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Abstract
The objective of this study was to characterize and compare muscle histopathological find-
ings in 3 different genetic motor neuron disorders. We retrospectively re-assessed muscle
biopsy findings in 23 patients with autosomal dominant lower motor neuron disease caused
by p.G66V mutation in CHCHD10 (SMAJ), 10 X-linked spinal and bulbar muscular atrophy
(SBMA) and 11 autosomal dominant c9orf72-mutated amyotrophic lateral sclerosis
(c9ALS) patients. Distinct large fiber type grouping consisting of non-atrophic type IIA mus-
cle fibers were 100% specific for the late-onset spinal muscular atrophies (SMAJ and
SBMA) and were never observed in c9ALS. Common, but less specific findings included
small groups of highly atrophic rounded type IIA fibers in SMAJ/SBMA, whereas in c9ALS,
small group atrophies consisting of small-caliber angular fibers involving both fiber types
were more characteristic. We also show that in the 2 slowly progressive motor neuron disor-
ders (SMAJ and SBMA) the initial neurogenic features are often confused with considerable
secondary “myopathic” changes at later disease stages, such as rimmed vacuoles, myofi-
brillar aggregates and numerous fibers reactive for fetal myosin heavy chain (dMyHC) anti-
bodies. Based on our findings, muscle biopsy may be valuable in the diagnostic work-up of
suspected motor neuron disorders in order to avoid a false ALS diagnosis in patients with-
out clear findings of upper motor neuron lesions.
Introduction
Histopathological analysis of muscle is not required for the diagnosis of amyotrophic lateral
sclerosis (ALS) and neurologists rarely perform muscle biopsy on motor neuron disease
patients when the diagnosis is not in doubt. Nevertheless, several neurogenic entities may clini-
cally simulate myopathies, and some myopathies such as LMNA-mutated muscular dystro-
phies and inclusion body myositis may also show neurogenic features. In these cases muscle
biopsy is likely to provide diagnostically useful information. Slow (type I) and fast (type II)
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muscle fibers are usually distributed in a checkerboard or mosaic-like pattern in healthy mus-
cles. Because lower motor neurons define the fiber types of innervated muscle fibers (either fast
or slow), reinnervation of denervated fibers by axonal sprouts from surviving motor neurons
typically leads to grouping of muscle fibers of the same type. This is considered the myopatho-
logical hallmark of neurogenic change.
We recently described a new slowly progressive type of adult-onset spinal muscular atrophy
caused by a c.197G>T p.G66V mutation in CHCHD10 [1] (SMAJ, OMIM #615048). Many of
the patients had initially been diagnosed as ALS, which carries a much less favourable progno-
sis than SMAJ. Primary diagnostic evaluations in our SMAJ patients indicated that muscle
biopsy findings were dissimilar in SMAJ compared with ALS, and therefore a study to detail
the differential features was needed. To this end, we compared three distinct genetic motor
neuron diseases: spinal and bulbar muscular atrophy (SBMA), c9orf72-related ALS (c9ALS)
and SMAJ. In addition, for selected SMAJ cases we evaluated the expression of CHCHD10 pro-
tein in muscle tissue by immunohistochemistry, and examined skeletal muscle mitochondrial
ultrastructure by electron microscopy.
Materials and Methods
Patient characteristics
Clinical features of the SMAJ patients have previously been reported1. All patients were geneti-
cally confirmed. CAG-repeat numbers in SBMA-patients ranged between 40 and 53 (median
45) repeats. SBMA/SMAJ patients had usually been symptomatic for several years before
undergoing first neurological examinations (Table 1). 1 SBMA and 4 SMAJ patients had dis-
ease durations of more than 20 years. Common features in SBMA and SMAJ patients were
cramping and fasciculations, lower limb onset of weakness and reduced or absent tendon
reflexes. 8 c9ALS patients died or were respirator-dependent within a mean of 3.3 years after
disease onset (range 2–5.5 years) and 3 were alive but disabled 1.5–3.5 years from onset.
In patients with only cramps but no clinical muscle weakness or atrophy, we arbitrarily
defined the disease duration as 0 years, if the muscle biopsy had been taken at the same time
when EMG confirmed a neurogenic disorder. All biopsies were obtained from a clinically or
electrophysiologically affected muscle.
Patients provided a written informed consent for the muscle biopsies. This retrospective
study was approved by the Tampere University Hospital (Tampere, Finland) Ethics Committee.
Muscle biopsies
We re-assessed all muscle biopsies from 23 SMAJ, 10 SBMA and 11 c9ALS patients evaluated
at Tampere Neuromuscular Research Center. 1 c9ALS and 1 SMAJ patient underwent 2 biop-
sies each. The quadriceps muscle, usually vastus lateralis, was biopsied in 7 SMAJ, 6 SBMA, 8
c9ALS patients and tibialis anterior muscle in 12 SMAJ, 4 SBMA and 2 c9ALS patients. Soleus,
deltoid and medial gastrocnemius muscles were biopsied in 3 (2 SMAJ, 1 c9ALS), 2 (1 SMAJ
and 1 c9ALS) and 2 SMAJ patients, respectively. Fresh frozen cryostat sections of muscle tissue
were stained with routine histochemical and immunohistochemical techniques [2,3]. In 1
SBMA patient, only MyHC double staining was performed and in 2 other SBMA patients, oxi-
dative enzyme stainings had not been performed. All other c9ALS, SMAJ and SBMA biopsies
were assessed for haematoxylin&eosin (H&E), Gomöri trichrome, major histocompatibility
complex (MHC) class I, fetal and neonatal myosin heavy chains (MyHCd and MyHCn), and
the oxidative enzyme stainings: nicotineamide adenine dinucleotide tetrazolium reductase
(NADH-TR) and combined cytochrome oxidase (COX)/succinate dehydrogenase (SDH).
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Additional immunohistochemical stainings were performed with the Ventana BenchMark
immunoautomate (Roche Tissue Diagnostics, Inc AZ 85755) in 1 SBMA and 3 SMAJ patients,
and the antibodies and their dilutions are listed in Table 2. Ventana peroxidase based detection
kit (UltraView Universal DAB detection system kit, Roche Tissue Diagnostics, Inc. AZ 85755)
was used for visualization.
Biopsies of 3 SMAJ patients were used for CHCHD10 immunohistochemistry and ultra-
structural studies. Semithin and ultrathin sections were performed with routine methods [4]
and the specimens were examined with JEOL 1400 transmission electron microscope (JEOL,
Japan). Electron micrographs were obtained with the Olympus-SIS Morada digital camera
(Olympus Soft Imaging Solutions, Munster, Germany).
Fiber type grouping was defined as the presence of both type I and type II fibers clustered in
solid groups. We subdivided this into “mild grouping” when the groups contained 1 fiber of
the same fiber type entirely surrounded by fibers of the same type, and “extensive grouping”
when at least 2 fibers of the same type were entirely surrounded by fibers of the same type.
Small group atrophies contained two or more adjacent angular fibers of the same fiber type
Table 1. Comparison of muscle histopathological findings in different genetic motor neuron disorders. All P values in the right-most column apply to
comparisons of both C9ALS versus SBMA and C9ALS versus SMAJ. None of the differences between SMAJ and SBMA groups were statistically significant.
SMAJ = spinal muscular atrophy, Jokela type, SBMA = spinal and bulbar muscular atrophy, C9ALS = amyotrophic lateral sclerosis caused by pathological
hexanucleotide expansion in the geneC9orf72. NA = not available.
Patient group
C9ALS (12 biopsies, 11
patients mean age 63, SD 9.7
years)
SBMA (10 biopsies,
mean age 59, SD 8.7
years)
SMAJ (24 biopsies, 23
patients, mean age 55, SD 13
years)
Median diseaseduration at
biopsy (range)
1 (0.5–1.5)years 7.5 (2–20) years 4.5 (0–24) years P value (Chi
square test)
Mild or extensive ﬁber type
grouping
67%(8/12) 10(100%) 24 (100%)
Duration 0–5 years 67% 100% 100%
Duration >6 years NA 100% 100%
Extensive ﬁber type grouping 25%(3/12) 90%(9/10) 88%(21/24) <0.05
Duration 0–5 years 25%(3/12) 80% (4/5) 92%(12/13)
Duration > 6 years NA 100%(5/5) 82% (9/11)
Large ﬁber typegrouping composed
of non-atrophic IIA ﬁbers
0% (0/12) 40%(4/10) 58%(14/24) <0.05
Duration 0–5 years 0% 60% (3/5) 85% (11/13)
Duration > 6 years NA 20% (1/5) 27% (3/11)
Small group atrophy 92%(11/12) 30%(3/10) 33%(8/24) <0.05
Duration 0–5 years 92%(11/12) 40% (2/5) 38%(5/13)
Duration > 6 years NA 20% (1/5) 45%(5/11)
Large group atrophy 25%(3/12) 50%(5/10) 50%(12/24) Not signiﬁcant
Duration 0–5 years 25%(3/12) 60% (3/5) 38%(5/13)
Duration > 6 years NA 40% (2/5) 64% (7/11)
Groups of small rounded IIA/IIX
ﬁbers
33% (4/12) 80% (8/10) 79%(19/24) <0.05
Duration 0–5 years 33% (4/12) 80% (4/5) 77%(10/13)
Duration > 6 years NA 80% (4/5) 82% (9/11)
Small group atrophy with mixed
ﬁber types
75% (9/12) 10% (1/10) 33% (8/24) <0.05
Duration 0–5 years 75% (9/12) 20% (1/5) 23% (3/13)
Duration > 6 years NA 0%(0/5) 45% (5/11)
doi:10.1371/journal.pone.0151376.t001
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(either type I or II) or consisted of mixed fiber types (both types I and II). Groups of highly
atrophic IIA/IIX fibers consisted of several adjacent, mostly rounded, fibers with diameters of
<20 micrometers (Fig 1). Large group atrophies were composed of extensive fiber type group-
ing of atrophic fibers, and non-atrophic IIA fiber groups had to display extensive fiber type
grouping of non-atrophic type IIA fibers, ie. with diameters of more than 50–60 micrometers.
Statistical analysis
Mean and standard deviation or median with range, were used to report descriptive statistics,
as appropriate. Comparisons of dichotomous variables between groups were performed with
Chi Square test. P = 0.05 was considered the threshold of statistical significance.
Results (Table 1)
Neurogenic biopsy findings
Extensive grouping of normal sized type IIA fibers (Fig 1) was a common finding in the SMAJ
and SBMA biopsies (in 58% and 40% of biopsies, respectively). These large non-atrophic IIA
groups were 100% specific for the benign motor neuron disease group, as they were not
encountered in any of the 12 c9ALS biopsies. Interestingly, these groups had already developed
early in some SMAJ/SBMA patients with normal strength and short duration of disease, which
is of importance regarding the time point of diagnostic evaluations. The presence of non-atro-
phic IIA groups declined over time, as 14/18 (78%) of SMAJ/SBMA displayed them when dis-
ease duration was 0–5 years as compared with 4/16 (25%) of biopsies performed in patients
with disease courses of 6–24 years. Grouping of non-atrophic IIA fibers was not restricted to
only certain anatomical muscles, as it was found in vastus lateralis, tibialis anterior and deltoid.
In c9ALS, small group atrophy and atrophic groups containing mixed fiber types were com-
mon features. Fiber type grouping was usually only mild and focal in c9ALS.
Groups of highly atrophic rounded type IIA fibers were frequently observed in SMAJ/SBMA,
but rarely in c9ALS patients.
Table 2. Antibodies used for immunohistochemistry, dilutions and suppliers.
Antibody Dilution Supplier
Myotilin 1:50 Leica Biosystems, Novocastra
AlphaBC 1:10 Leica Biosystems, Novocastra
Desmin 1:800 Biogenex
Dystrophin-2 1:100 Leica Biosystems, Novocastra
SMI-31 1:1000 Biosite
TDP-43 1:175 Proteintech Europe
P62 (SQSTM1) 1:100 Santa Cruz Biotechnology
Ubiquitin 1:300 Dako
LAMP2 1:50 Southern Biotech
LC3b 1:50 Cell Signaling Technology
VCP 1:600 Thermo Scientiﬁc
FHL-1 1:200 Lifespan Biosciences
Myosin Heavy Chain, Slow 1:200 Leica Biosystems
Myosin Heavy Chain, A4.74 (fast) 1:100 Developmental Studies Hybridoma Bank
Myosin Heavy Chain, developmental 1:40 Leica Biosystems
Myosin Heavy Chain, neonatal 1:20 Leica Biosystems
CHCHD10 1:10 Novus Biologicals
doi:10.1371/journal.pone.0151376.t002
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Other muscle pathology findings
Although all biopsies showed findings compatible with a primary neurogenic mechanism”se-
condary myopathic” changes were also frequent findings. Fatty replacement, fibrosis, internal
nuclei and fiber splitting were commonly observed in all 3 groups, but when present, these
findings were usually more abundant in SMAJ/SBMA. Hypertrophic fibers, defined as
markedly hypertrophic (muscle fiber diameter>130 micrometers) or mildly hypertrophic
(muscle fiber diameter 100–130 micrometers) occurred most commonly in SMAJ/SBMA but
were also observed in some c9ALS biopsies.
Neonatal myosin heavy chain (MHCn) positive fibers were found in all biopsies, ranging
between 1%-50% of the total number of fibers (median 12.5%) in c9ALS, 10%-50% (median
20%) in SBMA and 3%-50% (median 15%) in SMAJ. As expected in a neurogenic disorder,
fetal myosin heavy chain (MHCd) positive fibers were much less frequent, with a median of
1% of fibers in all groups, ranging between 0%-5%, 0.5%-10% and 0%-20% of fibers in c9ALS,
SBMA and SMAJ biopsies, respectively.
Fibers with poorly defined moth-eaten areas of myofibrillar disorganization on oxidative
enzyme stainings were a common biopsy finding in all disease groups. Occasional muscle sam-
ples in all disease groups contained fibers with core-like areas and lobulated fibers, but only
focally. Target and/or targetoid fibers were relatively rare, and were not restricted to any disease
group, but were more common in c9ALS samples than in SMAJ and SBMA. Rimmed vacuo-
lated fibers were present in 7 SMAJ, 4 SBMA and 4 c9ALS patient muscle biopsies, although in
only 2 SMAJ, 1 SBMA and 1 c9ALS patient biopsies were present in several fibers. 2 patients in
the SMAJ group and 2 in the SBMA group showed prominent myofibrillar protein aggregate
pathology on H&E and Gomöri trichrome -staining. In the SBMA group, myofibrillar aggre-
gates and rimmed vacuolar pathology were most prominent in the patient with the longest dis-
ease duration (20 years) and in the one carrying the highest CAG-repeat number of 53 repeats
(Fig 2). For 2 SMAJ and 1 SBMA patient samples with more prominent rimmed vacuolar
Fig 1. Neurogenic muscle biopsy findings in SMAJ, SBMA and c9ALS. Small groups of rounded type IIA
fibers (arrows) in a vastus lateralis muscle biopsy of a 48-year-old male with SMAJ (A). Extensive fiber type
grouping involving non-atrophic type IIA fibers (arrows) shown in a tibialis anterior biopsy of a 55-year-old
SMAJ female patient (B). Groups of angulated atrophic fibers with mixed fiber types (arrows) in a vastus
lateralis muscle of a 52-year-old female patient with c9ALS (C). Small groups of extremely atrophic type IIA
fibers (inset) in a tibialis anterior biopsy of a 60-year-old male patient with SBMA (D). Figs A-D: myosin heavy
chain double stain immunohistochemistry showing type IIA fibers in red, IIX fibers in blue and type I fibers in
brown color. Scale bar = 100 micrometers
doi:10.1371/journal.pone.0151376.g001
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Fig 2. Secondary “myopathic” changes in SMAJ. 2: Unusually pronounced myofibrillar and autophagic pathology in a gastrocnemius medialis biopsy of a
67-year-old female with SMAJ. H&E and herovici stainings (A and E) showing endomysial fibrosis, fiber size variation, internal nuclei, as well as large
myofibrillar aggregates (asterisk, A-B, E-G), several rimmed vacuolated fibers (vertical arrows) and one”cytoplasmic body” aggregate (black horizontal
arrow). The myofibrillar aggregates are strongly myotilin immunoreactive (B) and show also some reactivity for p62 and SMI-31 (F and G). The rimmed
vacuolar areas contain LC3 (C) and ubiquitin (D) positive material (with our antibody and protocol nuclei are also stained besides ubiquitinated cytoplasmic
material). The rimmed vacuolated fibers are also strongly reactive for p62, SMI-31 and TDP-43 (F-H).
doi:10.1371/journal.pone.0151376.g002
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pathology, we performed further immunohistological evaluations for Z-disc components
(myotilin, desmin, alphaB-crystallin, BAG3), dystrophin carboxy terminal (DYS-2) and autop-
hagy markers (LC3b, VCP, TDP-43, SMI-31, p62). The results are shown in Table 3 and Figs 2
and 3. The myofibrillar lesions were strongly myotilin and alphaB-crystallin immunopositive
and ectopic dystrophin expression was usually present in the same fiber regions. In the rimmed
vacuolated fibers protein aggregates were immunoreactive for markers of autophagic process-
ing, including ubiquitin, p62, SMI-31, TDP-43, VCP and LC3b.
Minor, focal inflammatory infiltrates were observed in 4 SMAJ and one c9ALS biopsy and
weak, patchy sarcolemmal staining with MHC class I antibodies was present in 5 SMAJ and 4
c9ALS biopsies. A few ragged red and COX-deficient fibers were an occasional finding in all 3
patient groups. The total number of ragged red fibers and COX-deficient fibers did not exceed
1% or 3% of the total number of fibers, respectively, in any of the muscle samples.
CHCHD10 immunohistochemistry and ultrastructural evaluation of
SMAJ biopsies
Because of the unexpected lack of mitochondrial muscle pathology in SMAJ in contrast to the
findings previously reported with another CHCHD10 mutation [5], we further performed
CHCHD10 immunohistochemistry and ultrastructural studies in 3 SMAJ patients to examine
the mitochondria in more detail. In normal control muscle the mitochondrial CHCHD10 pro-
tein was more abundant in type I fibers, as expected. However, there was no difference in over-
all expression or localisation between normal and SMAJ patient muscle samples (Fig 4). For
electron microscopy we selected patients with variable disease durations (less than 1 year in 2
and 7 years in 1), aged 42–67 years at the time of biopsy. The 67-year-old patient showed the
most marked mitochondrial pathology of any SMAJ patient on light microscopic level, but dis-
played only 3% COX-deficient and 1% ragged red fibers. The other two patients showed only a
few or no COX-deficient fibers. Ultrastructurally, the number and size of the mitochondria
was in the normal range in all of the examined biopsies, and no abnormal mitochondrial
aggregates were found. The morphology of cristae was within the normal range and no
Table 3. Additional immunohistochemical studies in SMAJ and SBMA patients with rimmed vacuoles and/or myofibrillar pathology. ND = not
defined, alphaBC = alphaB-crystallin, Dys-2 = dystrophin c-terminus, SMAJ = SMA Jokela type, SBMA = spinal and bulbar muscular atrophy, RV = rimmed
vacuoles, CA = “cytoplasmic body” aggregates, VL = vastus lateralis, Gcmed = gastrocnemius medialis. -, normal or no immunoreactivity; +, immunoreactivity
present/mild abnormality; ++ moderate immunoreactivity/abnormality; +++, high immunoreactivity/abnormality.
SMAJ #1 (Soleus) SMAJ #2(Gcmed) SMAJ #3(VL) SBMA #1(VL)
Appearanceon
routinestains(H&E,
Gomöri)
RV +++, secondarymyopathic/
dystrophicfeatures
Myoﬁbrillaraggregates++,
CA ++,RV +++
RV +,
mildmyoﬁbrillaraggregates
RV ++,CA++,
myoﬁbrillar
aggregates
Myotilin + +++ + +
AlphaBC + ++ + +
Desmin - + - +
Dys-2 + ++ - +
SMI-31 +++ +++ + -
TDP-43 +++ +++ - +
P62 +++ +++ + +
Ubiquitin ++ ++ + +
LAMP-2 slightly increased increased normal normal
VCP + ++ - -
FHL1 ND - ND ND
LC3b +++ +++ + +
doi:10.1371/journal.pone.0151376.t003
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paracrystalline inclusions were identified. Only some of the mitochondria were degenerated
corresponding to a nonspecific alteration in injured muscle cells.1 short duration SMAJ patient
showed small subsarcolemmal tubular aggregates (Fig 4F), which were not evident on light
microscopic evaluation, including NADH and Gomöri trichrome staining. The patient’s only
symptom was widespread cramping of muscles.
Discussion
The finding of extensive grouping with non-atrophic type IIA fibers was the major distinguish-
ing feature in patients with the slow, less severe variants of motor neuron disease (SMAJ and
SBMA), and was not observed in c9ALS patients. This is in line with previous observations that
fiber type grouping without significant atrophy is associated with slowly progressive, well-com-
pensated neurogenic processes [6]. However, the occurrence and significance of this important
finding in adult-onset motor neuron diseases has not previously been appreciated.
Fig 3. Secondary “myopathic” changes in SBMA.Muscle biopsy from a vastus lateralis biopsy of a 46-year-old male patient with SBMA showing internal
nuclei, rimmed vacuoles (RV, yellow arrows, A-B), one RV and”cytoplasmic body” aggregate (green arrow), core-lobulated fibers with myofibrillar aggregates
(black arrows in A-B, yellow arrows in C) that are strongly myotilin immunoreactive (yellow arrows, D).
doi:10.1371/journal.pone.0151376.g003
Muscle Biopsy in Motor Neuron Disorders
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Additionally we observed that the frequency of groups of non-atrophic IIA fibers declined
over time in SBMA/SMAJ patients, as they were observed in 78% of patients with a disease
duration 0–5 years, as opposed to only 25% of biopsies from patients with more protracted dis-
ease duration (6–24 years). The most obvious explanation for this would be that there is a bet-
ter capacity for reinnervation at the early disease stages, and this process decreases with the
continuous loss of motor neurons. By contrast, the presence of secondary myopathic changes
seemed to increase with longer disease duration and caused diagnostic difficulties in some
patients. The SMAJ/SBMA patients with most marked “myopathic” changes including promi-
nent rimmed vacuolar pathology and high amounts (5–20%) of MHCd-positive fibers always
had long disease durations (10–20 years) or, in one SBMA patient, an unusually large CAG-
repeat. In addition, the second biopsy of the only c9ALS patient that was biopsied twice showed
significantly more “myopathic” changes than the first specimen. In part these “myopathic”
changes are likely to be adaptive or compensatory efforts by the myofibers, but in SBMA a pri-
mary myopathic component may also exist. [7]
Another mutation, c.176C>T p.S59L, in the CHCHD10 gene was reported with a different
phenotype, frontotemporal dementia (FTD)/ALS with mitochondrial myopathy [5]. We have
Fig 4. Lack of mitochondrial abnormalities in SMAJ. Immunohistochemical CHCHD10 staining in normal
muscle sample (A) and muscle sample from SMAJ patient (C) showing no difference in expression and
location of CHCHD10. The CHCHD10 staining is more prominent in type 1 fibers. The corresponding myosin
double stainings are shown of the same muscles (B, D). Electron micrographs from deltoideus muscle of a
42-year-old SMAJ patient showmorphologically normal mitochondria beneath the sarcolemma (E) and a
subsarcolemmal tubular aggregate (F).
doi:10.1371/journal.pone.0151376.g004
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previously reported that SMAJ patients do not show major mitochondrial pathology in muscle
at the light microscopic level, in contrast to the S59L-mutated CHCHD10 patients with ALS/
FTD [1]. The present study shows that the mitochondrial CHCHD10 protein is normally
expressed on immunohistochemistry and confirms that the mitochondria of SMAJ patients
were normal also when examined ultrastructurally.
Potential sources of bias in this work include the number biopsies in each group which is
related to the availability of material, and that the re-evaluation was not blinded for the final
diagnosis. Furthermore, only a proportion of patients with SMAJ and SBMA had undergone a
muscle biopsy. However, the first routine diagnostic evaluation of biopsies nearly always pre-
dated molecular genetic diagnoses, and our non-biopsied SMAJ/SBMA patients had a very
similar disease course as the biopsied ones selected for this study [8].
According to one study, atrophic groups consisting of mixed fiber types were more common
in motor neuron disease biopsies (ALS and SBMA) than in polyneuropathies [9]. We found
atrophic mixed fiber type groups to be frequent in c9ALS (75% of biopsies), while they were
less common in SMAJ (33%) and SBMA (10%) biopsies. However, comparison with the previ-
ous work is not straightforward, because the authors did not report the results per patient but
rather per high power fields examined [9].
The boundaries between myopathies, lower motor neuron disease and central nervous sys-
tem disorders have recently become blurred, with the discovery of a CHCHD10mutation in
mitochondrial myopathy associated with FTD/ALS (OMIM #615911), whereas the allelic dis-
order, SMAJ, causes a mild lower motor neuron disease and no cognitive decline. Furthermore,
different mutations inMATR3-related disease may cause either ALS [10] or distal myopathy
[11], and dementia/lower motor neuron syndrome can coexist with myopathies due to VCP
mutations (OMIM #167320). Sporadic inclusion body myositis may also be confused with ALS
clinically and on electromyography. All these syndromes differ significantly from classical ALS,
and their proper identification is greatly facilitated by muscle histopathological investigations.
Muscle biopsy may therefore be valuable in the diagnostic work-up of unclear motor neuron
disorders, in order to provide patients with an accurate diagnosis and prognosis.
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